Positive News SentimentPositive NewsNASDAQ:RLYB Rallybio (RLYB) Stock Price, News & Analysis $0.40 +0.02 (+5.60%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$0.40 0.00 (-0.20%) As of 06/10/2025 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Rallybio Stock (NASDAQ:RLYB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rallybio alerts:Sign Up Key Stats Today's Range$0.36▼$0.4350-Day Range$0.25▼$0.4552-Week Range$0.22▼$1.73Volume277,396 shsAverage Volume122,766 shsMarket Capitalization$16.47 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company OverviewRallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.Read More… Rallybio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreRLYB MarketRank™: Rallybio scored higher than 43% of companies evaluated by MarketBeat, and ranked 479th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingRallybio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageRallybio has only been the subject of 4 research reports in the past 90 days.Read more about Rallybio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rallybio are expected to grow in the coming year, from ($1.34) to ($1.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rallybio is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rallybio is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRallybio has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Rallybio's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.80% of the float of Rallybio has been sold short.Short Interest Ratio / Days to CoverRallybio has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Rallybio has recently decreased by 1.79%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRallybio does not currently pay a dividend.Dividend GrowthRallybio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.80% of the float of Rallybio has been sold short.Short Interest Ratio / Days to CoverRallybio has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Rallybio has recently decreased by 1.79%, indicating that investor sentiment is improving. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Rallybio this week, compared to 1 article on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Rallybio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.70% of the stock of Rallybio is held by insiders.Percentage Held by Institutions90.34% of the stock of Rallybio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rallybio's insider trading history. Receive RLYB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rallybio and its competitors with MarketBeat's FREE daily newsletter. Email Address RLYB Stock News HeadlinesRallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlookMay 24, 2025 | investing.comRallybio shareholders elect directors, ratify auditorMay 18, 2025 | uk.investing.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.June 11, 2025 | Paradigm Press (Ad)Rallybio Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 9, 2025 | finance.yahoo.comRallybio to Present at the 2025 Citizens JMP Life Sciences ConferenceApril 29, 2025 | finance.yahoo.comJones Trading Downgrades Rallybio (RLYB)April 15, 2025 | msn.comRallybio downgraded to Hold from Buy at JonesResearchApril 14, 2025 | markets.businessinsider.comRallybio downgraded to In Line from Outperform at Evercore ISIApril 12, 2025 | markets.businessinsider.comSee More Headlines RLYB Stock Analysis - Frequently Asked Questions How have RLYB shares performed this year? Rallybio's stock was trading at $0.96 at the beginning of the year. Since then, RLYB shares have decreased by 58.8% and is now trading at $0.3958. View the best growth stocks for 2025 here. How were Rallybio's earnings last quarter? Rallybio Co. (NASDAQ:RLYB) announced its earnings results on Thursday, May, 8th. The company reported ($0.21) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.21). The firm had revenue of $0.21 million for the quarter. When did Rallybio IPO? Rallybio (RLYB) raised $80 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 5,750,000 shares at $13.00-$15.00 per share. Who are Rallybio's major shareholders? Top institutional investors of Rallybio include Canaan Partners XI LLC (3.68%) and Allostery Investments LP (1.81%). Insiders that own company stock include Kush Parmar and Jonathan I Lieber. View institutional ownership trends. How do I buy shares of Rallybio? Shares of RLYB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rallybio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rallybio investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Plug Power (PLUG). Company Calendar Last Earnings5/08/2025Today6/10/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RLYB CIK1739410 Webwww.rallybio.com Phone203-59-3820FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$15.00 Low Stock Price Target$5.00 Potential Upside/Downside+2,426.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.56 million Net MarginsN/A Pretax Margin-10,794.48% Return on Equity-77.39% Return on Assets-69.33% Debt Debt-to-Equity RatioN/A Current Ratio9.55 Quick Ratio9.55 Sales & Book Value Annual Sales$848 thousand Price / Sales19.42 Cash FlowN/A Price / Cash FlowN/A Book Value$2.81 per share Price / Book0.14Miscellaneous Outstanding Shares41,614,000Free Float38,418,000Market Cap$16.47 million OptionableNot Optionable Beta-1.24 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:RLYB) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rallybio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.